Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Fate Therapeutics Inc
FATECurrent price
2.08 USD
-0.1 USD (-4.59%)
Last closed
2.17 USD
Company
www.fatetherapeutics.com
ISIN
US31189P1021
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
275 584 768 USD
Yield for 12 month
-16.13 %
1Y
3Y
5Y
10Y
15Y
FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.58 USDP/E ratio
–Dividend Yield
–Current Year
+63 533 000 USD
Last Year
+96 300 000 USD
Current Quarter
+6 772 000 USD
Last Quarter
+1 925 000 USD
Current Year
+45 251 000 USD
Last Year
+96 300 000 USD
Current Quarter
+2 051 000 USD
Last Quarter
-2 896 000 USD
Key Figures FATE
1 year
3 years
5 years
10 years
EBITDA
-163 438 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.5 %
PEG Ratio
–
Return On Equity TTM
-42.1 %
Wall Street Target Price
6.58 USD
Revenue TTM
12 317 000 USD
Book Value
3.49 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
625.8 %
Dividend Yield
–
Gross Profit TTM
-224 154 000 USD
Earnings per share
-1.7 USD
Diluted Eps TTM
-1.7 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics FATE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FATE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation FATE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
5.7401
Price Sales TTM
22.3743
Enterprise Value EBITDA
-2.5897
Price Book MRQ
0.6928
Financials FATE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators FATE
For 52 weeks
2.05 USD
8.83 USD
50 Day MA
3.24 USD
Shares Short Prior Month
14 175 946
200 Day MA
4.57 USD
Short Ratio
14.27
Shares Short
16 063 774
Short Percent
16.19 %
BeatStart